BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder

NCT00839397 | Completed Phase 3

• 1 other identifier: 29060/799
• Study Type: interventional
• Target: 52
• Locations: 0 countries
• Sites: N/A

Brief Summary

This was a 52-week, non-comparative, uncontrolled study of paroxetine in Japanese PTSD patients to obtain clinical experience regarding efficacy and safety. In this study, subjects received paroxetine 20mg-40mg once daily after an evening meal.

Conditions

Post-Traumatic Stress Disorder

Outcome Measures

Primary Outcomes (1)

• Change from baseline in the Clinician-Administered Posttraumatic Stress Disorder Scale One Week Symptom Status Version (CAPS-SX) total score

  52 weeks

Secondary Outcomes (6)

• Proportion of responders based on the CGI Global Improvement

  52 weeks

• Change from baseline in the CAPS-SX re-experiencing cluster score

  52 weeks

• Change from baseline in the CAPS-SX avoidance/numbing cluster score

  52 weeks

• Change from baseline in the CAPS-SX hyperarousal cluster score

  52 weeks

• Change from baseline in the CGI Severity of Illness score

  52 weeks

Study Arms (1)

Paroxetine

OTHER

A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)

Drug: Paroxetine

Interventions

Paroxetine DRUG

Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response ("1. Very much improved" or "2. Much improved" based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted. Dosage adjustment will be made at the discretion of the PI or Sub-PI

Paroxetine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with a primary diagnosis of PTSD according to DSM-IV criteria (Posttraumatic Stress Disorder: 309.81). In order to diagnose PTSD, the Clinician-Administered PTSD Scale-DX Current and Lifetime Diagnostic Version (CAPS-DX) will be used.
• Disease to Be Treated:
• Duration of illness of at least 3 months at Week -1.
• Score \>= 50 on Criteria B, C and D of CAPS-SX.
• Age: \>=18 - \<65 years (at the time of acquisition of informed consent)
• Sex: No restriction
• Hospitalization Status: No restriction
• Informed consent: Gives his/her informed consent. In case of a subject who is under the age of 20, his/her parent/guardian must also give his/her written informed consent.

You may not qualify if:

• Patients diagnosed with Axis I disorders (excluding PTSD) such as major depression, dysthymia, simple phobia, OCD, or panic disorder as a primary diagnosis according to DSM-IV criteria within 24 weeks prior to Week -1. However, patients with depressive disorders are allowed to enroll in the study, if PTSD was present before the depressive disorders appeared and PTSD is the predominant disorder.
• Patients presenting a current major depressive episode that preceded the diagnosis of PTSD. However, patients with depressive disorders are allowed to enroll in the study, if PTSD was present before the depressive disorders appeared and PTSD is the predominant disorder.
• Patients receiving disability payments because of PTSD or any other psychiatric disorder.
• Patients currently engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders.
• Patients taking St. Johns Wort.
• Patients who meet DSM-IV criteria for substance abuse (alcohol or drugs) or substance dependence within 24 weeks prior to Week -1.
• Patients who have attempted suicide within 24 weeks prior to Week -1 or who pose, in the investigator's judgement using the M.I.N.I. "C. Suicidality", a high suicidal risk.
• Women who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study.
• Patients who have taken MAO inhibitors within 1 week prior to Week -1 (or within 2 weeks prior to Week 0).
• Patients who have had electroconvulsive therapy (ECT) within 12 weeks prior to Week -1.
• Patients who have been treated with another investigational drug within 12 weeks prior to Week -1.
• Patients with a history or complication of manic psychosis.
• Patients with a history or complication of convulsive disorder (epilepsy, etc.).
• Patients with a complication of glaucoma.
• Patients with a known tendency for bleeding or those with predisposing conditions.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Related Publications (1)

• Kim Y, Asukai N, Konishi T, Kato H, Hirotsune H, Maeda M, Inoue H, Narita H, Iwasaki M. Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. Psychiatry Clin Neurosci. 2008 Dec;62(6):646-52. doi: 10.1111/j.1440-1819.2008.01862.x.

  PMID: 19068000 BACKGROUND

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Interventions

Paroxetine

Condition Hierarchy (Ancestors)

Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2009
• First Posted: February 9, 2009
• Study Start: May 1, 2002
• Primary Completion: November 1, 2004
• Study Completion: June 1, 2005
• Last Updated: March 10, 2014

Record last verified: 2014-03